Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer ; volume:9 ; number:1 ; day:27 ; month:9 ; year:2023 ; pages:1-16 ; date:12.2023
npj Breast cancer ; 9, Heft 1 (27.9.2023), 1-16, 12.2023
- Urheber
-
Cosgrove, Nicola
Eustace, Alex J.
O’Donovan, Peter
Madden, Stephen F.
Moran, Bruce
Crown, John
Moulton, Brian
Morris, Patrick G.
Grogan, Liam
Breathnach, Oscar
Power, Colm
Allen, Michael
Walshe, Janice M.
Hill, Arnold D.
Blümel, Anna
O’Connor, Darren
Das, Sudipto
Milewska, Małgorzata
Fay, Joanna
Kay, Elaine
Toomey, Sinead
Hennessy, Bryan T.
Furney, Simon J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-023-00572-9
- URN
-
urn:nbn:de:101:1-2024020512440633540526
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cosgrove, Nicola
- Eustace, Alex J.
- O’Donovan, Peter
- Madden, Stephen F.
- Moran, Bruce
- Crown, John
- Moulton, Brian
- Morris, Patrick G.
- Grogan, Liam
- Breathnach, Oscar
- Power, Colm
- Allen, Michael
- Walshe, Janice M.
- Hill, Arnold D.
- Blümel, Anna
- O’Connor, Darren
- Das, Sudipto
- Milewska, Małgorzata
- Fay, Joanna
- Kay, Elaine
- Toomey, Sinead
- Hennessy, Bryan T.
- Furney, Simon J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy